Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 2 | 2022 | 47 | 0.960 |
Why?
|
| Acalculous Cholecystitis | 1 | 2024 | 1 | 0.940 |
Why?
|
| Gangrene | 1 | 2024 | 4 | 0.940 |
Why?
|
| Plasmablastic Lymphoma | 5 | 2021 | 9 | 0.920 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2021 | 6 | 0.700 |
Why?
|
| HIV Infections | 10 | 2022 | 4946 | 0.460 |
Why?
|
| Male | 16 | 2024 | 6489 | 0.420 |
Why?
|
| Hodgkin Disease | 4 | 2021 | 10 | 0.410 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2022 | 11 | 0.400 |
Why?
|
| Microsatellite Instability | 2 | 2022 | 5 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2021 | 7 | 0.360 |
Why?
|
| Humans | 20 | 2024 | 14077 | 0.350 |
Why?
|
| Retrospective Studies | 6 | 2022 | 767 | 0.300 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2021 | 16 | 0.290 |
Why?
|
| Herpesvirus 4, Human | 3 | 2021 | 5 | 0.270 |
Why?
|
| Adult | 10 | 2024 | 5664 | 0.270 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 12 | 0.260 |
Why?
|
| South Africa | 11 | 2022 | 7312 | 0.250 |
Why?
|
| Cannabinoids | 1 | 2024 | 1 | 0.240 |
Why?
|
| Burkitt Lymphoma | 2 | 2021 | 3 | 0.230 |
Why?
|
| Microsatellite Repeats | 1 | 2022 | 14 | 0.210 |
Why?
|
| HIV | 2 | 2019 | 380 | 0.210 |
Why?
|
| Middle Aged | 11 | 2021 | 3425 | 0.210 |
Why?
|
| Heart Aneurysm | 1 | 2001 | 2 | 0.200 |
Why?
|
| Lymphoma, B-Cell | 4 | 2021 | 11 | 0.190 |
Why?
|
| Heart Ventricles | 1 | 2001 | 60 | 0.190 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 2020 | 1 | 0.180 |
Why?
|
| Bone Marrow | 1 | 2020 | 19 | 0.180 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2017 | 4 | 0.180 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 3 | 0.170 |
Why?
|
| Female | 12 | 2021 | 8751 | 0.170 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 25 | 0.170 |
Why?
|
| Lymphoma | 1 | 2017 | 4 | 0.150 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 10 | 0.150 |
Why?
|
| Herpesvirus 8, Human | 1 | 2017 | 14 | 0.140 |
Why?
|
| Young Adult | 5 | 2021 | 2357 | 0.120 |
Why?
|
| Adolescent | 5 | 2021 | 2858 | 0.110 |
Why?
|
| In Situ Hybridization | 2 | 2021 | 10 | 0.100 |
Why?
|
| Gene Rearrangement | 2 | 2021 | 15 | 0.100 |
Why?
|
| Aged | 5 | 2021 | 1650 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 1275 | 0.090 |
Why?
|
| Immunophenotyping | 2 | 2021 | 24 | 0.090 |
Why?
|
| Incidence | 2 | 2021 | 655 | 0.080 |
Why?
|
| Child | 3 | 2019 | 2180 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1377 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 5 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 8 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 32 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 449 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2001 | 6 | 0.050 |
Why?
|
| Cell Survival | 1 | 2021 | 45 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 33 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2001 | 35 | 0.050 |
Why?
|
| Genes, myc | 1 | 2021 | 6 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 26 | 0.050 |
Why?
|
| Echocardiography | 1 | 2001 | 99 | 0.050 |
Why?
|
| Gene Dosage | 1 | 2021 | 23 | 0.050 |
Why?
|
| STAT Transcription Factors | 1 | 2020 | 1 | 0.050 |
Why?
|
| Janus Kinases | 1 | 2020 | 1 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2020 | 33 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 6 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 106 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 60 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 299 | 0.040 |
Why?
|
| Logistic Models | 1 | 2019 | 252 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 103 | 0.040 |
Why?
|
| HIV Seronegativity | 1 | 2017 | 52 | 0.040 |
Why?
|
| Herpesviridae Infections | 1 | 2017 | 2 | 0.040 |
Why?
|
| Prevalence | 2 | 2011 | 1149 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 939 | 0.030 |
Why?
|
| Lymphoma, Follicular | 1 | 2015 | 2 | 0.030 |
Why?
|
| North America | 1 | 2015 | 11 | 0.030 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 4 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 15 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 53 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 322 | 0.030 |
Why?
|
| Africa, Southern | 1 | 2015 | 89 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 1431 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 106 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 263 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 468 | 0.030 |
Why?
|
| Hemangiosarcoma | 1 | 1994 | 2 | 0.030 |
Why?
|
| Heart Neoplasms | 1 | 1994 | 5 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1994 | 52 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 150 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2010 | 165 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 260 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2010 | 266 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2010 | 1675 | 0.020 |
Why?
|
| Infant | 1 | 2010 | 2145 | 0.010 |
Why?
|
| HIV-1 | 1 | 2011 | 1239 | 0.010 |
Why?
|
| Castleman Disease | 1 | 1994 | 1 | 0.010 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 1994 | 1 | 0.010 |
Why?
|
| Heart Atria | 1 | 1994 | 7 | 0.010 |
Why?
|
| Disease Progression | 1 | 1994 | 154 | 0.010 |
Why?
|